https://www.omninanopharma.com/home daily 1.0 2026-02-04 https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/d909ec4a-dedd-4cb4-a521-b32c5e339811/Artboard+3%402x.png Home https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/74af2226-3516-4cda-8e8b-2585a003380f/Artboard+2%402x.png https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/9f4100ca-0bc8-49e3-aa1a-08e200f78aea/Before%402x.png https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/a6584531-8c1b-417d-b502-dc92d3df5922/After%402x.png https://www.omninanopharma.com/team daily 0.75 2026-02-03 https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/4a89291f-1be8-484e-9e01-06bc9c9a0d24/Leslie%2BSloan-New.png Team https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/d774d02f-f8e4-46f4-bf28-fc80dc45dcae/Chun_Li_1-new.png Team https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/0acd3911-f37f-4952-8a98-22e9e4705cf7/Diana-New.png Team https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/ff47361d-4145-4488-9609-3eba15610f39/gourong-ma-new.png Team https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/a4d3d575-fa97-4ff1-83c4-ae81faa62dcd/Artboard+1+copy+2%402x.png Team https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780270536-L8FRGDXI7CCSNEJDBFDE/GH1G_J7W4AAtpZR.jpeg Team https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780270546-IHN4FM1TF2DBPOUDM27T/F351E80F-0528-4228-BE9B-090712DBF448_4_5005_c.jpeg Team https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/51d14cb1-c80c-49af-94a6-58186f09a4c7/AH-New.png Team https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/d89dd1c6-4868-4eee-b392-8ffa831bb9b5/Artboard+1+copy%402x.png Team https://www.omninanopharma.com/news daily 0.75 2026-01-30 https://www.omninanopharma.com/home-copy daily 0.75 2026-01-30 https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273598-TGOXHHYCN05V6ULMZY35/Mice_Gut.jpg Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273621-YNOH8SPWHHAYAAWTCFL9/Heart.jpg Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273643-UJX0KLYZHY8ZZ32FPWJL/Lung.jpg Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273693-IITP7ZTALT9197QUFVKR/Liver.jpg Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273711-YRUH4ETMYRJQ3Z61974O/Spleen.jpg Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273730-61CG0ZARPEBYY1ABDL03/Small_Bowel.jpg Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273770-JHI0P4TDQZI5A5HIN8O8/Kidney.jpg Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273356-KLJKFGAZZGYR0XXKH96K/Stats_Image_1.png Home (Copy) - Future Expectations PDAC is expected to become the second leading cause of cancer-related deaths by 2030. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis statistics based on the lack of early detection. PDAC accounts for more than 90% of pancreatic cancer cases. https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273374-M46F4AKNC4Q1GGUWG0PI/Stats_Image_2.png Home (Copy) - Future Expectations HCC is expected to become the third leading cause of cancer-related deaths by 2030. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, making up more than 80% of cases in the United States. HCC has a poor prognosis and is typically diagnosed late in its course. https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273392-2KCZZHG0KQDFHVFU4KCB/Omninano_cancer_cell_small.png Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273415-4RMG01P5OLBH37ETUSVQ/Omninano_vials.png Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273432-A4LLL2X8UFK2B6OUGMVQ/Omninano_Patient_Smiling.jpg Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273471-ALYSCQLL4JZVWT4XSTJH/Omninano_Diagram.png Home (Copy) https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273489-A8Q3HMWRP8UK4U8QQ0XR/OmniNano_Graphs-01.png Home (Copy) - Positive outlook M-CPA/PTX demonstrated remarkable antitumor activity in KPC GEMM of PDAC. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit. https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273514-OR88K3TEV6733JCXBQ3K/OmniNano_Graphs-02.png Home (Copy) - Positive outlook M-CPA/PTX is highly efficacious against PDAC in KPC mice (late treatment). Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit. https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273534-CO264HNQC77SHY3FSH5D/OmniNano_Graphs-03.png Home (Copy) - Positive Outlook M-CPA/PTX demonstrated remarkable antitumor activity in c-Myc-driven GEMM of liver cancer. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit. https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273551-4O32N45V37YURQ43YJ5T/OmniNano_Graphs-04.png Home (Copy) - Positive outlook M-CPA/PTX effectively delivered both CPA and PTX to pancreatic cancer In Vivo. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit. https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273787-3PZZVRNQF60HSJLDUVQE/Omninao_Doctor_Patient.jpg Home (Copy) - Pancreatic & Liver Cancer Market Pancreatic Cancer U.S. New Cases in 2021: 60,430 The Global Pancreatic Cancer Therapeutics Market was worth USD 2.6 billion in 2021 and estimated to be growing at a CAGR of 7.54%, to reach USD 3.7 billion by 2026. Liver Cancer U.S. New Cases in 2021: 42,230 The Liver Cancer Treatment Market was worth USD 2.0 billion in 2020 and is projected to reach USD 7.3 billion by 2028, growing at a CAGR of 17.7% from 2021 to 2028. https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273833-DMQKG6HBZF09NL4N2BKR/Omninano_syringes.jpg Home (Copy) - Pancreatic & Liver Cancer Competitive Market Pancreatic Cancer: There are only 4 FDA approved chemotherapeutics: ABRAXANE, Gemcitabine, 5 FU, and Irinotecan Liposome Injection. In addition, FOLFIRINOX (combination of 5 FU/ Leucovorin, Irinotecan, and Oxaliplatin) is commonly used for metastatic cancer. These treatments provide only a marginal survival benefit over no therapy. Liver Cancer: Approved therapeutics include Sorafenib Monotherapy (Rafi/ VEGFRi) which has an OS of 9.2-10.7 months, and Bevacizumab plus Atezolizumab (anti-VEGF + anti-PD-L1) whose OS is better than the Sorafenib Monotherapy. https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780273850-K60LI1QBQ6B0Y76MJYPQ/Omninano_blue_nano.jpg Home (Copy) - Competitive Landscape for Nano-Paclitaxel Protein-bound paclitaxel, also known as nanoparticle albumin-bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. It’s delivery vehicle is albumin. https://www.omninanopharma.com/press-releases daily 0.75 2026-01-30 https://www.omninanopharma.com/cookie-policy daily 0.75 2026-01-30 https://www.omninanopharma.com/contact daily 0.75 2026-02-02 https://images.squarespace-cdn.com/content/v1/5ce435d6bea1ed00016ba287/1558964652247-5MWXNMFZVOPGE4TY6U2Q/MHeiderich_ReflexionenZwei-05-copy.jpg Contact https://www.omninanopharma.com/privacy-policy daily 0.75 2026-01-30 https://www.omninanopharma.com/terms-of-service daily 0.75 2026-01-30 https://www.omninanopharma.com/new-page daily 0.75 2026-02-03 https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/d774d02f-f8e4-46f4-bf28-fc80dc45dcae/Chun_Li_1-new.png https://www.omninanopharma.com/new-page-1 daily 0.75 2026-02-03 https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/4a89291f-1be8-484e-9e01-06bc9c9a0d24/Leslie%2BSloan-New.png https://www.omninanopharma.com/new-page-2 daily 0.75 2026-02-03 https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/0acd3911-f37f-4952-8a98-22e9e4705cf7/Diana-New.png https://www.omninanopharma.com/new-page-1-1 daily 0.75 2026-02-03 https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/ff47361d-4145-4488-9609-3eba15610f39/gourong-ma-new.png https://www.omninanopharma.com/new-page-1-1-1 daily 0.75 2026-02-03 https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780270536-L8FRGDXI7CCSNEJDBFDE/GH1G_J7W4AAtpZR.jpeg https://www.omninanopharma.com/new-page-1-1-1-1 daily 0.75 2026-02-03 https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/1769780270546-IHN4FM1TF2DBPOUDM27T/F351E80F-0528-4228-BE9B-090712DBF448_4_5005_c.jpeg https://www.omninanopharma.com/new-page-2-1 daily 0.75 2026-02-03 https://images.squarespace-cdn.com/content/v1/697cb42b4883114008fc71aa/51d14cb1-c80c-49af-94a6-58186f09a4c7/AH-New.png